〔Abstract〕 Objective To investigate the application value of cilostazol combined with ticagrelor or clopidogrel in reducing major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). Methods A total of 143 patients with AMI who received PCI in the First Affiliated Hospital of Nanyang Medical College from January 2018 to May 2020 were selected and divided into an observation group (72 cases) and a control group (71 cases) by simple randomization. The control group was treated with cilostazol combined with clopidogrel, and the observation group was treated with cilostazol combined with ticagrelor for 1 month. The left ventricular ejection fraction (LVEF), platelet aggregation rate before and after treatment and the occurrence of MACE 6 months after treatment were compared between the two groups. Results After treatment, the levels of LVEF in 2 groups were higher those before treatment, and platelet aggregation rate were lower than those before treatment, and LVEF in the observation group was higher than that in the control group, and platelet aggregation rate was lower than that in the control group, , the differences were statistically significant (P < 0.05). There was no significant difference in the total incidence of MACE between the two groups (P > 0.05). Conclusion The safety of cilostazol combined with ticagrelor or combined with clopidogrel after PCI was similar in patients with AMI, but cilostazol combined with ticagrelor had a better effect on left heart function after PCI in patients with AMI.